“…Despite their great performance characteristics, immunoassays are prone to interferences that may alter tests results, putting patients at risk for misdiagnosis [12]. All biotin-(strept)avidin-based immunoassays are susceptible to interference with biotin, but the degree of risk for patient misdiagnosis can vary considerably between immunoassays [40].…”
Section: Biotin Interferencementioning
confidence: 99%
“…Immunoassays are routinely used in laboratory diagnostics [12] due to their utilization of highly specific antibodies that exhibit remarkable diversity to selectively target a vast variety analytes of interest and measure their concentrations in a sample [13]. Antibodies are the key reagents on which the success of the immunoassay depends [6], relying on their ability to bind to a specific area of an antigen called an epitope [11].…”
An immunoassay is an analytical test method in which analyte quantitation is based on signal responses generated as a consequence of an antibody–antigen interaction. They are the method of choice for the measurement of a large panel of diagnostic markers. Not only are they fully automated, allowing for a short turnaround time and high throughput, but offer high sensitivity and specificity with low limits of detection for a wide range of analytes. Many immunoassay manufacturers exploit the extremely high affinity of biotin for streptavidin in their assay design architectures as a means to immobilize and detect analytes of interest. The biotin–(strept)avidin system is, however, vulnerable to interference with high levels of supplemental biotin that may cause elevated or suppressed test results. Since this system is heavily applied in clinical diagnostics, biotin interference has become a serious concern, prompting the FDA to issue a safety report alerting healthcare workers and the public about the potential harm of ingesting high levels of supplemental biotin contributing toward erroneous diagnostic test results. This review includes a general background and historical prospective of immunoassays with a focus on the biotin–streptavidin system, interferences within the system, and what mitigations are applied to minimize false diagnostic results.
“…Despite their great performance characteristics, immunoassays are prone to interferences that may alter tests results, putting patients at risk for misdiagnosis [12]. All biotin-(strept)avidin-based immunoassays are susceptible to interference with biotin, but the degree of risk for patient misdiagnosis can vary considerably between immunoassays [40].…”
Section: Biotin Interferencementioning
confidence: 99%
“…Immunoassays are routinely used in laboratory diagnostics [12] due to their utilization of highly specific antibodies that exhibit remarkable diversity to selectively target a vast variety analytes of interest and measure their concentrations in a sample [13]. Antibodies are the key reagents on which the success of the immunoassay depends [6], relying on their ability to bind to a specific area of an antigen called an epitope [11].…”
An immunoassay is an analytical test method in which analyte quantitation is based on signal responses generated as a consequence of an antibody–antigen interaction. They are the method of choice for the measurement of a large panel of diagnostic markers. Not only are they fully automated, allowing for a short turnaround time and high throughput, but offer high sensitivity and specificity with low limits of detection for a wide range of analytes. Many immunoassay manufacturers exploit the extremely high affinity of biotin for streptavidin in their assay design architectures as a means to immobilize and detect analytes of interest. The biotin–(strept)avidin system is, however, vulnerable to interference with high levels of supplemental biotin that may cause elevated or suppressed test results. Since this system is heavily applied in clinical diagnostics, biotin interference has become a serious concern, prompting the FDA to issue a safety report alerting healthcare workers and the public about the potential harm of ingesting high levels of supplemental biotin contributing toward erroneous diagnostic test results. This review includes a general background and historical prospective of immunoassays with a focus on the biotin–streptavidin system, interferences within the system, and what mitigations are applied to minimize false diagnostic results.
“…8,[17][18][19] The origin of anti-streptavidin antibodies is unknown, but may be due to prior exposure to streptavidin or the soil bacterium, Streptomyces avidinii, from which the protein is purified. 19 Anti-ruthenium antibodies directed to either ruthenium or the ruthenium-labelled antibodies may result in an increase or a decrease in the chemiluminescent signal, which in turn may lead to inaccurately elevated or decreased hormone results depending on the interfering antibody specificity and assay format. 7,20…”
Section: Heterophile and Human Anti-animal Antibodiesmentioning
confidence: 99%
“…free T3) ( Figure 7B ). 8 , 17 – 19 The origin of anti-streptavidin antibodies is unknown, but may be due to prior exposure to streptavidin or the soil bacterium, Streptomyces avidinii , from which the protein is purified. 19 …”
Section: Interference With Assay Componentsmentioning
For over 50 years, immunoassays have been extensively used to quantitate hormones in blood, other fluids and tissues. Each assay has its own sensitivity, specificity and other analytical components. Despite the differences between commercial products, these assays provide important clinical information about hormone levels in patients. However, inaccurate results can occur because of technical issues, as well as patient-specific factors that can interfere with immunoassay hormone measurements. The latter include excessive normal blood or serum components, the presence of cross-reacting substances, extremely high levels of hormones leading to the high-dose hook effect, and interference from a variety of endogenous factors such as human antibodies that interact with the assay components or high levels of biotin in the serum from exogenous ingestion. This article briefly reviews the sources and recognition of endogenous interference, and describes methods to determine the correct serum hormone concentration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.